Overview
Publication
J Infect Dis. 2022 Jan 18; 225(2):332-340.
PubMed ID: 34174082
Title
Analysis of neutralizing antibodies as a correlate of instantaneous risk of hospitalized dengue in placebo recipients of dengue vaccine efficacy trials
Authors
Huang Y, Williamson BD, Moodie Z, Carpp LN, Chambonneau L, DiazGranados CA , Gilbert PB
Abstract
In the CYD14 (NCT01373281) and CYD15 (NCT01374516) dengue vaccine efficacy trials, month 13 neutralizing antibody (nAb) titers correlated inversely with risk of symptomatic, virologically confirmed dengue (VCD) between month 13 (1 month after final dose) and month 25. We assessed nAb titer as a correlate of instantaneous risk of hospitalized VCD (HVCD), for which participants were continually surveilled for 72 months.
With the publicly available data in the CAVD DataSpace we can Learn about studies, products, assays, antibodies, and publications, Find subjects with common characteristics, Plot assay results across studies and years of research, and Compare monoclonal antibodies and their neutralization curves. Data are also accessible via DataSpaceR, our R API.
Sign in to see full information about this publication and to download study data when available.
Related Studies
No related studies